Dimethyl fumarate
- Generic Name
- Dimethyl fumarate
- Brand Names
- Tecfidera, Skilarence, Dimethyl fumarate Neuraxpharm, Dimethyl fumarate Mylan, Dimethyl fumarate Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C6H8O4
- CAS Number
- 624-49-7
- Unique Ingredient Identifier
- FO2303MNI2
- Background
Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis. The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MMF up-regulates the Nuclear factor (erythroid-derived 2)-...
- Indication
Dimethyl fumarate is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
- Associated Conditions
- Clinically Isolated Syndrome (CIS), Relapsing Forms of MS, Relapsing Remitting Multiple Sclerosis (RRMS), Active Secondary Progressive Multiple Sclerosis (SPMS)
- Associated Therapies
- -
Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera
- Conditions
- Interventions
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1507
- Registration Number
- NCT04756687
- Locations
- 🇫🇷
Research Site, Île-de-France - Salpêtrière, France
Relationship Between Oral DMT Burden and Adherence in MS
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2022-08-31
- Lead Sponsor
- Monash University
- Target Recruit Count
- 323
- Registration Number
- NCT04676204
- Locations
- 🇦🇺
Monash University, Melbourne, Victoria, Australia
Randomised Evaluation of COVID-19 Therapy
- Conditions
- Interventions
- Drug: Lopinavir-RitonavirBiological: Convalescent plasmaBiological: ImmunoglobulinDrug: CorticosteroidDrug: Synthetic neutralising antibodiesDrug: EmpagliflozinDrug: AnakinraDrug: High Dose CorticosteroidDrug: SotrovimabDrug: PaxlovidDrug: Baloxavir MarboxilDrug: HydroxychloroquineDrug: AzithromycinDrug: TocilizumabDrug: AspirinDrug: Dimethyl fumarateDrug: ColchicineDrug: BaricitinibDrug: OseltamivirDrug: Molnupiravir
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 70000
- Registration Number
- NCT04381936
- Locations
- 🇻🇳
Oxford University Clinical Research Unit, Centre for Tropical Medicine, Ho Chi Minh City, Vietnam
🇬🇭Kumasi Center for Collaborative Research in Tropical Medicine KNUST, Kumasi, Ghana
🇮🇳Indian Council of Medical Research, Division of Epidemiology and Communicable Diseases, New Delhi, India
Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP
- Conditions
- Interventions
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Biogen
- Target Recruit Count
- 353
- Registration Number
- NCT04221191
- Locations
- 🇫🇷
Pole de Sante Du Plateau, Clamart, France
🇫🇷Cabinet du Dr Pierre Gras, Dijon, France
🇫🇷Cabinet médical Montebello, Lille, France
Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants
- Conditions
- Interventions
- First Posted Date
- 2019-03-12
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Biogen
- Target Recruit Count
- 11
- Registration Number
- NCT03870763
- Locations
- 🇹🇷
Research Site, Samsun, Turkey
Teriflunomide Tecfidera LMCE
- First Posted Date
- 2018-05-16
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- University at Buffalo
- Target Recruit Count
- 120
- Registration Number
- NCT03526224
- Locations
- 🇺🇸
Buffalo Neuroimaging Analysis Center, Buffalo, New York, United States
Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2019-10-31
- Target Recruit Count
- 55
- Registration Number
- NCT03345940
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Neurologico C. Besta, Neuroimmunology Unit, Milan, Italy
Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2018-03-22
- Target Recruit Count
- 57
- Registration Number
- NCT03092544
- Locations
- 🇺🇸
Multiple Sclerosis Center of Northeastern New York, Latham, New York, United States
A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2
- Conditions
- Interventions
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Biogen
- Target Recruit Count
- 506
- Registration Number
- NCT03093324
- Locations
- 🇵🇱
Alkermes Investigational Site, Szczecin, Poland
Study of Utilization Patterns of Dimethyl Fumarate in Germany
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2017-07-19
- Lead Sponsor
- Biogen
- Target Recruit Count
- 930
- Registration Number
- NCT02969304
- Locations
- 🇩🇪
Research Site, Leipzig, Saxony, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.